Posted by Michael Wonder on 29 May 2025
Zydus receives US FDA fast track designation for usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis
28 May 2025 - Usnoflast has previously also received orphan drug designation from the US FDA.
Zydus today announced that the US FDA has granted fast track designation to usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis.
